Vincere Biosciences has been given $700,000 in seed funding by the National Institutes of Health (NIH) to advance in testing USP30 small molecule inhibitors, its candidate therapy aiming to slow or stop progression in Parkinson’s disease. Valid for two years, the Phase I Small Business…
The Parkinson’s Foundation and CurePSP have partnered on a new, multi-part educational program for healthcare professionals that’s aimed at helping frontline workers better understand atypical parkinsonism. Its overarching goals are improved diagnosis and care. The Atypical Parkinsonism Program focuses on three disease types: progressive supranuclear palsy (PSP), corticobasal…
Newer glucose-lowering drugs used to treat type 2 diabetes, compared with a placebo, appear to lower a person’s risk of Parkinson’s disease, according to a meta-analysis of controlled clinical trials. Findings suggest a potential association between recent classes of anti-diabetic medications and the risk of developing Parkinson’s, and they…
In people with Parkinson’s disease, the cerebral cortex of the brain can compensate for disease-related dysfunction in the basal ganglia, the main part of the brain affected by Parkinson’s. Researchers found that patients with milder Parkinson’s symptoms have more compensatory activity in the cerebral cortex, while patients with…
Interfering with the circadian clock, or the body’s internal clock, may make dopaminergic neurons — the nerve cells that become progressively lost in Parkinson’s disease — more prone to damage at night, according to a study in fruit flies. “Our results further suggest that genetic variations in circadian clock…
Pupil light reflex (PLR), the automatic contraction or dilation of the eye’s pupil in response to light levels, was found to be impaired in people with Parkinson’s disease in a small study. Impaired PLR is believed to contribute to the vision problems experienced by some Parkinson’s patients. New data…
Patients who are on long-term levodopa to treat Parkinson’s disease are more likely to experience self-reported freezing of gait, or FOG, than levodopa-naïve (untreated) patients, a study has found. These findings suggest that FOG should be taken into account when studying Parkinson’s, with “the ultimate aim to develop…
Significant alterations in the structure and function of the eye’s retina — the layer at the very back of the eyeball that’s key in transmitting information to the brain — were revealed in adults with Parkinson’s disease in a new study. Data demonstrated a significant impact of disease duration…
The mutated form of alpha-synuclein protein — a key player in the development of Parkinson’s disease — can travel in the brain to various regions using the brain’s immune system before it builds up into toxic clumps, or aggregates, a new study has found.
People with Parkinson’s disease whose electrical brain wave activity declines more slowly during deep sleep develop levodopa-induced dyskinesia (LID), or uncontrolled movements, faster, a study has found. These findings confirm a link between sleep-related brain wave activity and LID, and support the development of sleep-targeted therapies that may protect…
Get regular updates to your inbox.
